Loading clinical trials...

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin

NCT02384369•Synchroneuron Inc.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled study of SNC-102 in adult subjects with cPTSD, added to pre-existing treatment that includes prazosin with or without other psychotropic drugs. Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks. Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder (cPTSD) as measured by the Clinician Administered PTSD Scale (CAPS-5), compared with the response to placebo.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmation of a diagnosis by a Board-Certified psychiatrist of combat-related posttraumatic stress disorder (cPTSD) according to Diagnostic and Statistical Manual (DSM-5) criteria for PTSD and a history linking the symptoms to combat exposure.
•Taking prazosin for treatment of cPTSD for a minimum of 4 weeks, on a stable dose for at least 2 weeks, and expected to remain on that dose for the duration of the study.
•Having sufficient residual symptoms of PTSD while on the current drug regimen that, in the opinion of the Principal Investigator, additional treatment of the disorder is clinically indicated.
•Body mass index of 18-38 kg/m2 inclusive.

Exclusion Criteria

•Plans to initiate a new psychotropic medication (other than the study drug) during the period of the study.
•Plans to change the dose or discontinue prazosin or a psychotropic medication during the period of the study.
•Diagnosis of epilepsy or treatment with an antiepileptic drug.
•Use of alcohol or cannabis to the extent that, in the view of the Principal Investigator, it raises a significant risk of medication noncompliance, drinking alcohol after midnight on the days of study visits or missed study visits. Any use of non-prescribed opiates, cocaine, or other street drugs other than cannabis in the month prior to study entry.
•Any history of major medical complications of alcohol use including alcoholic hepatitis, cirrhosis of the liver, pancreatitis, alcohol withdrawal seizures, or delirium tremens.
•Patients taking moderate, stable doses of oral opiates for chronic pain may be admitted at the discretion of the Principal Investigator.
•Current use of a drug other than prazosin with significant alpha-adrenergic blocking effects, if associated with symptomatic orthostatic hypotension.
•Current use of cocaine, amphetamine, phencyclidine, or ketamine, documented either by history or by urinary drug screening at Screening and Baseline Visits. Urinary drug screening for ketamine and phencyclidine will conducted off-site by the Study Sponsor if urinary drug screening available at the study site does not include these drugs. Any other drugs identified incidentally on drug screening will warrant exclusion only if the Principal Investigator, in consultation with the Sponsor, judges that their presence could interfere with the objectives of the trial.
•Pregnant or lactating female.
•Women of childbearing potential, unless the subject agrees to use dual contraceptive methods while on study drug and for 1 month afterward, which, in the opinion of the Principal Investigator, are effective and adequate for that subject's circumstances.
+2 more criteria

Key Dates

Start Date

June 1, 2016

Primary Completion Date

June 1, 2017

Completion Date

August 1, 2017

Last Updated

April 18, 2016

Conditions

Post-Traumatic Stress DisordersPosttraumatic Stress DisordersStress Disorders, Post-TraumaticPost-Traumatic Stress Disorders, Combat-related

Interventions

SNC-102 sustained release tablet

DRUG

PTSD Treatment for Veterans With Serious Mental Illness to Improve Functional Outcomes

NCT05674617

Stress Disorders, Post-Traumatic; Mental Disorders

View study

RECRUITINGNA

Enhancing Memory in CPT for PTSD

NCT06000475

Stress Disorders, Post-Traumatic

View study

RECRUITINGNA

Group-based Stabilization and Skill Training for Patients With Lasting Posttraumatic Reactions in Mental Health Care

NCT03887559

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 18, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

Inclusion Criteria

Exclusion Criteria

PTSD Treatment for Veterans With Serious Mental Illness to Improve Functional Outcomes

Enhancing Memory in CPT for PTSD

Group-based Stabilization and Skill Training for Patients With Lasting Posttraumatic Reactions in Mental Health Care

Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication

Trauma-Informed Guilt Reduction Therapy Compared to Prolonged Exposure

Mental Health in Veterans and Families After Group Therapies